While two mega-suitors battled over Synthes, the Swiss medical giant was busy boosting sales and reporting health growth in earnings.

Synthes saw 11 percent growth in revenues during the three months ended June 30, posting $992 million in sales compared to $892 million during the same period last year.

While the company doesn’t break down its financials further for the quarter, its six-month report shows 7 percent growth in earnings to $454 million, or $3.83 per diluted share, compared to $425 million, or $3.58 per diluted share during the first half of 2010.

Rumors were flying in April that Johnson & Johnson (NYSE:JNJ), which ranked 2nd on the MassDevice Big 100 list of the world’s largest medical companies, was ready to put down $20 billion for Synthes, rumors which were confirmed soon after.

JNJ closed the deal for $21.3 million, 40 percent which was to be in cash and the rest in JNJ common stock.

By July the details of the deal had emerged, revealing the buyout to be a tale of two suitors. A consortium of three private equity firms courted Synthes with an all-cash deal that nearly won the Swiss orthopedics specialist’s heart.

Synthes’ merger with JNJ is expected to close in the first half of 2012.

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple days:

Mindray stays strong
Mindray Medical International Ltd. (NYSE:MR) saw a big boost in sales in the three months ended June 30. The Shenzhen, China-based device company posted a 21 percent increase in sales to $217 million, compared to $179 million during the same period last year.

Company profits rose 6 percent to $44.8 million, or 37 cents per diluted share, compared to $179 million, or 36 cents per diluted share in Q2 of 2010.
Read more

CardioNet see slight dip in sales, huge dip in losses
CardioNet Inc. (NSDQ:BEAT) saw sinking profits in the three months ended June 30. The Conshohocken, Pa.-based wireless diagnostic and monitoring device company posted a 1 percent dip in sales to $31.6 million, compared to $31.9 million during the same period last year.

Company losses increase 43 percent to a loss of $3 million, or 12 cents lost per diluted share, compared to $2.1 million, or a loss of 9 cents per diluted share in Q2 of 2010.
Read more

CareFusion delivers strong sales and earnings
CareFusion Corp. (NYSE:CFN)  saw a strong fourth quarter for the three months ended June 30. The San Diego, Calif.-based med-tech giant company posted a 4 percent increase in sales to $964 million, compared to $930 million during the same period last year.

Company profits soared 63 percent to $85 million, or 37 cents per diluted share, compared to $52 million, or 23 cents per diluted share in Q2 of 2010.
Read more

Alphatec grows sales but stays red
Alphatec Holdings Inc. (NSDQ:ATEC)  stayed in the red in the three months ended June 30. The Carlsbad, Calif.-based spinal company posted a 12 percent increase in sales to $51 million, compared to $45 million during the same period last year.

Company losses widened 2 percent to $3.04 million, or 3 cents per diluted share, compared to $2.98 million, or 4 cents per diluted share in Q2 of 2010.
Read more